Overview

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The outcome for children with high-grade gliomas and diffuse intrinsic brainstem gliomas remains poor despite the use of multi-modal therapy with surgery, radiation therapy and chemotherapy.
Phase:
Early Phase 1
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Camptothecin
Dacarbazine
Irinotecan
Temozolomide